Baseline Modern Medical Management in the BEST-CLI Trial.
暂无分享,去创建一个
J. Beckman | T. Huber | M. Jaff | N. Choudhry | K. Tuttle | C. White | I. Weinberg | T. Hamza | L. Clavijo | A. Drooz | M. Conte | M. Cziraky | K. Rosenfield | A. Farber | A. Schanzer | I. Laskowski | M. Menard | M. Strong | Maxwell Van Over
[1] Manesh R. Patel,et al. Understanding Study Drug Discontinuation Through EUCLID , 2022, Frontiers in cardiovascular medicine.
[2] V. Huckell,et al. Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. , 2022, The Canadian journal of cardiology.
[3] R. Eckel,et al. National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020 , 2022, Journal of the American Heart Association.
[4] P. Chu,et al. Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a retrospective multi-institutional study. , 2021, Diabetes research and clinical practice.
[5] J. Golledge,et al. A meta-analysis of randomised controlled trials evaluating the efficacy of smoking cessation interventions in people with peripheral artery disease. , 2021, Journal of vascular surgery.
[6] Manesh R. Patel,et al. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. , 2021, Journal of the American College of Cardiology.
[7] N. Hamburg,et al. Racial and Ethnic Disparities in Peripheral Artery Disease , 2021, Circulation research.
[8] M. Creager,et al. Contemporary Medical Management of Peripheral Artery Disease , 2021, Circulation research.
[9] David W. Johnson,et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials , 2021, BMJ.
[10] J. Schensul,et al. Black-white Disparities in Social and Behavioral Determinants of Health Index and Their Associations with Self-rated Health and Functional Limitations in Older Adults. , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.
[11] M. Creager,et al. Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[12] Dorairaj Prabhakaran,et al. 2020 International Society of Hypertension global hypertension practice guidelines. , 2020, Journal of hypertension.
[13] Khendi T White Solaru,et al. Evidence-Based Medical Management of Peripheral Artery Disease , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[14] John V. White,et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. , 2019, Journal of vascular surgery.
[15] K. Rosenfield,et al. The BEST‐CLI trial is nearing the finish line and promises to be worth the wait , 2019, Journal of vascular surgery.
[16] L. Tarnow,et al. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial , 2018, Diabetes Care.
[17] 6. Glycemic Targets: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.
[18] E. Amsterdam,et al. Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease. , 2017, The American journal of cardiology.
[19] L. Fleisher,et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.
[20] K. Mahaffey,et al. Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease , 2017, The New England journal of medicine.
[21] S. Assmann,et al. Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST‐CLI) Trial , 2016, Journal of the American Heart Association.
[22] K. Berger,et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. , 2015, European heart journal.
[23] M Hassan Murad,et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. , 2015, Journal of vascular surgery.
[24] Biykem Bozkurt,et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[25] H. Bang,et al. Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease , 2014, Journal of the American Heart Association.
[26] J. Beckman,et al. Secondary Prevention and Mortality in Peripheral Artery Disease: National Health and Nutrition Examination Study, 1999 to 2004 , 2011, Circulation.
[27] J. Bittl,et al. Concomitant peripheral arterial disease and coronary artery disease: therapeutic opportunities. , 2004, Circulation.
[28] K. Eagle,et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. , 2004, Journal of vascular surgery.
[29] Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy , 1994, BMJ.
[30] M. Caulfield,et al. Hypertension , 1931, The Lancet.
[31] A Ross Naylor,et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.
[32] M. Prins,et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. , 2003, The Cochrane database of systematic reviews.